Measles cases rise to 159 in Texas, state health department says
The Texas health department reported 159 measles cases in the state on Tuesday, an increase of 13 cases from its previous count.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Reporting by Puyaan Singh in Bengaluru; Editing by Arun Koyyur
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
06-05-2025
- Reuters
Dialysis firm FMC tops market expectations in 1st quarter
May 6 (Reuters) - World's largest dialysis specialist Fresenius Medical Care ( opens new tab reported first-quarter results above market expectations on Tuesday, as revenue grew organically in all its segments. The German company's revenue was 4.88 billion euros ($5.53 billion) in the quarter, slightly above analysts' average estimate of 4.85 billion in a poll compiled by Vara Research. That was up from 4.73 billion euros in the same period in 2024. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Operating income adjusted for special items grew to 457 million euros from 403 million euros last year, beating analysts' expectations of 446 million euros. While patient treatment in the U.S. took a hit from missed appointments in February due to high numbers of flu and cold cases, analysts were expecting those numbers to improve through March and April. FMC, which made 67% of its quarterly revenue through dialysis procedures in the United States, said payments from medical insurers and favourable U.S. dollar to euro exchange rate offset the decrease in dialysis days. The dialysis provider for 300,000 patients worldwide confirmed its guidance for 2025 and continues to expect market treatment growth in the U.S. to be more than 0.5% this year. ($1 = 0.8831 euros)
Reuters
05-05-2025
- Reuters
Trump to continue Biden's court defense of abortion drug mifepristone
Summary May 5 (Reuters) - President Donald Trump's administration on Monday pushed forward in defending U.S. rules easing access to the abortion drug mifepristone from a legal challenge that began during Democratic former President Joe Biden's administration. The U.S. Department of Justice in a brief filed in Texas federal court urged a judge to dismiss the lawsuit by three Republican-led states on procedural grounds. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. While the filing does not discuss the merits of the states' case, it suggests the Trump administration is in no rush to drop the government's defense of mifepristone, used in more than 60% of U.S. abortions. Missouri, Kansas and Idaho claim the U.S. Food and Drug Administration acted improperly when it eased restrictions on mifepristone, including by allowing it to be prescribed by telemedicine and dispensed by mail. The Justice Department and the office of Missouri Attorney General Andrew Bailey did not immediately respond to requests for comment. Trump said while campaigning last year that he did not plan to ban or restrict access to mifepristone. Health and Human Services Secretary Robert F. Kennedy Jr. told Fox News in February that Trump has asked for a study on the safety of abortion pills and has not made a decision on whether to tighten restrictions on them. Last year, the U.S. Supreme Court rejected a bid by anti-abortion groups and doctors to restrict access to the drug, finding that they lacked legal standing to challenge the FDA regulations. Those plaintiffs dropped their case after the high court ruling, but U.S. District Judge Matthew Kacsmaryk, a Trump appointee, allowed the states to intervene and continue to pursue the lawsuit. The U.S. Justice Department moved to dismiss their claims days before Trump took office in January. In Monday's filing, government lawyers repeated their arguments that Texas is not the proper venue for the lawsuit and that the states lack standing to sue because they are not being harmed by the challenged regulations. "Regardless of the merits of the States' claims, the States cannot proceed in this Court," they wrote. The three states are challenging FDA actions that loosened restrictions on the drug in 2016 and 2021, including allowing for medication abortions at up to 10 weeks of pregnancy instead of seven, and for mail delivery of the drug without a woman first seeing a clinician in-person. The original plaintiffs initially had sought to reverse FDA approval of mifepristone, but that aspect was rebuffed by a lower court. The Republican-led states have argued they have standing to sue because their Medicaid health insurance programs will likely have to pay to treat patients who have suffered complications from using mifepristone. They have also said they should be allowed to remain in Texas even without the original plaintiffs because it would be inefficient to send the case to another court after nearly more than two years of litigation.
Reuters
05-05-2025
- Reuters
Trump orders ban on federal funds for gain-of-function research seen as dangerous, Fox News reports
WASHINGTON, May 5 (Reuters) - U.S. President Donald Trump signed an executive order on Monday that bans federal funding for gain-of-function research seen as dangerous, Fox News reported, citing a White House statement. The order bans federal funding towards such research in China, Iran and other countries and aims to improve the safety and security of biological research, Fox News reported. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. The reported quoted the White House as saying the order "will drastically reduce the potential for lab-related incidents involving gain-of-function research, like that conducted on bat coronaviruses in China by the EcoHealth Alliance and Wuhan Institute of Virology."
